Date: 2011-10-12
Type of information: Grant
Company: Affiris (Austria)
Investors: The Michael J. Fox Foundation - MJFF (USA)
Amount: $ 1.5 million (€ 1.08 million)
Funding type: grant
Planned used: The award will be used to finance the clinical study of AFFITOPE® PD01, a first-of-its-kind Parkinson´s disease (PD) vaccine. AFFITOPE® PD01 targets and helps remove the alpha-synuclein protein, whose clumping is the pathological hallmark of PD.
Others: The Michael J.Fox Foundation has awarded $1.5 million to AFFiRiS AG, a Vienna, Austria-based biotech company for a clinical study of AFFITOPE® PD01, a first-of-its-kind Parkinson´s disease (PD) vaccine. AFFITOPE® PD01 targets and helps remove the alpha-synuclein protein, the major component in the Lewy bodies that are found in the brains of people with Parkinson´s. Pre-clinical studies show that the PD01 vaccine stimulates the body´s immune system to produce antibodies that bind to the protein alpha-synuclein, clearing it from the brain and slowing disease progression.
Therapeutic area: Neurodegenerative diseases
